231.97
2.29%
+5.19
Overview
News
Price History
Option Chain
Financials
Why BDX Down?
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson & Co. stock is currently priced at $231.97, with a 24-hour trading volume of 4.56M.
It has seen a +2.29% increased in the last 24 hours and a -1.12% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $225.9 pivot point. If it approaches the $230.8 resistance level, significant changes may occur.
Previous Close:
$226.78
Open:
$227.21
24h Volume:
4.56M
Market Cap:
$67.04B
Revenue:
$19.72B
Net Income/Loss:
$1.33B
P/E Ratio:
42.10
EPS:
5.51
Net Cash Flow:
$3.03B
1W Performance:
+1.39%
1M Performance:
-1.12%
6M Performance:
-1.78%
1Y Performance:
-4.05%
Becton Dickinson & Co. Stock (BDX) Company Profile
Name
Becton Dickinson & Co.
Sector
Industry
Phone
201 847 6800
Address
1 Becton Drive, Franklin Lakes
Becton Dickinson & Co. Stock (BDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-24-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-30-23 | Resumed | Morgan Stanley | Overweight |
May-05-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Apr-12-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Jan-03-23 | Upgrade | BofA Securities | Neutral → Buy |
Dec-12-22 | Upgrade | Citigroup | Sell → Neutral |
Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
Jun-24-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-18-22 | Resumed | Raymond James | Mkt Perform |
Mar-02-22 | Resumed | BofA Securities | Neutral |
Dec-08-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
May-25-21 | Initiated | Barclays | Equal Weight |
Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jul-09-20 | Upgrade | Barclays | Equal Weight → Overweight |
Jun-01-20 | Resumed | Goldman | Buy |
Mar-05-20 | Initiated | Citigroup | Neutral |
Feb-07-20 | Downgrade | Cowen | Outperform → Market Perform |
Feb-07-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Feb-07-20 | Downgrade | Raymond James | Strong Buy → Outperform |
Feb-06-20 | Downgrade | Cowen | Outperform → Market Perform |
Jan-08-20 | Downgrade | Barclays | Overweight → Equal Weight |
May-13-19 | Upgrade | Barclays | Equal Weight → Overweight |
Dec-07-18 | Initiated | Deutsche Bank | Buy |
Oct-16-18 | Initiated | Barclays | Equal Weight |
Jun-21-18 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-10-18 | Upgrade | Citigroup | Neutral → Buy |
Jan-19-18 | Resumed | BofA/Merrill | Buy |
Jan-05-18 | Upgrade | Citigroup | Sell → Neutral |
Jan-05-18 | Initiated | KeyBanc Capital Mkts | Overweight |
Jan-03-18 | Initiated | Evercore ISI | Outperform |
Dec-29-17 | Reiterated | Deutsche Bank | Buy |
View All
Becton Dickinson & Co. Stock (BDX) Latest News
Becton, Dickinson And Polaris: Market Is Wrong About These Dividend Aristocrat Bargains - Seeking Alpha
Seeking Alpha
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
MarketWatch
Becton, Dickinson and Company (NYSE:BDX) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Defense World
Goldman Sachs bullish on Becton Dickinson stock, citing new product growth By Investing.com - Investing.com
Investing.com
Should We Be Cautious About Becton, Dickinson and Company's (NYSE:BDX) ROE Of 5.1%? - Yahoo Movies UK
Yahoo Movies UK
Becton, Dickinson Beats on Revenue, Matches Expectations on EPS - AOL
AOL
Becton Dickinson & Co. Stock (BDX) Financials Data
Becton Dickinson & Co. (BDX) Revenue 2024
BDX reported a revenue (TTM) of $19.72 billion for the quarter ending March 31, 2024, a +4.82% rise year-over-year.
Becton Dickinson & Co. (BDX) Net Income 2024
BDX net income (TTM) was $1.33 billion for the quarter ending March 31, 2024, a -17.56% decrease year-over-year.
Becton Dickinson & Co. (BDX) Cash Flow 2024
BDX recorded a free cash flow (TTM) of $3.03 billion for the quarter ending March 31, 2024, a +164.74% increase year-over-year.
Becton Dickinson & Co. (BDX) Earnings per Share 2024
BDX earnings per share (TTM) was $4.54 for the quarter ending March 31, 2024, a -14.82% decline year-over-year.
Becton Dickinson & Co. Stock (BDX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Goette Roland | EVP and President EMEA |
May 15 '24 |
Sale |
236.73 |
3,300 |
781,224 |
11,308 |
Goette Roland | EVP and President EMEA |
May 13 '24 |
Sale |
236.70 |
3,300 |
781,121 |
14,608 |
Garrison Michael David | EVP & President Medical |
Apr 30 '24 |
Sale |
232.81 |
1,715 |
399,269 |
5,381 |
Spoerel Thomas J | SVP,Controller&Chief Acct Off |
Mar 14 '24 |
Sale |
238.29 |
282 |
67,198 |
2,276 |
Garrison Michael David | EVP & President Medical |
Dec 11 '23 |
Sale |
232.46 |
1,239 |
288,018 |
7,274 |
Byrd Richard | EVP & President Interventional |
Nov 28 '23 |
Sale |
238.47 |
2,156 |
514,141 |
4,120 |
Goette Roland | EVP and President, EMEA |
Nov 16 '23 |
Option Exercise |
107.12 |
3,544 |
379,633 |
17,164 |
Byrd Richard | EVP & President Interventional |
Sep 05 '23 |
Sale |
274.48 |
459 |
125,986 |
3,444 |
Fraser Claire | Director |
Aug 28 '23 |
Sale |
281.66 |
848 |
238,848 |
21,608 |
Hickey David | EVP & President, Life Sciences |
Aug 11 '23 |
Option Exercise |
132.54 |
3,883 |
514,653 |
9,030 |
About Becton Dickinson & Co.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. It has a strategic partnership with the Biomedical Advanced Research and Development Authority to develop new manufacturing lines for injection devices. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Cap:
|
Volume (24h):